Click here for the full story. Acumen brings in Alzheimer’s heavy hitter. Acumen Pharmaceuticals, a Charlottesville, Virginia biopharma developing a novel therapeutic for Alzheimer’s ...

Founded in 1935 by Khwaja Abdul Ahmeid, Cipla operates through two segments: Pharmaceuticals and New Ventures. Cipla Limited specialises in developing medications, primarily treating respiratory ...

Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil E-mail: [email protected] ...

How widespread are community-acquired infections due to emerging methicillin-resistant Staphylococcus aureus (MRSA) strains, and are these strains responsible for changes in the clinical spectrum ...

In the 5 patients with bilateral geographic atrophy (GA) who received a K8 implant in 1 eye, there was a mean reduction in GA lesion growth of 66% at 3 months.

The Risk Evaluation and Education for Alzheimer's Disease (REVEAL) Study is a recently completed randomized controlled trial (RCT) evaluating the impact of a genetic education and counseling ...

Dry macular degeneration is a common eye disorder among people aged above 50 years. It causes blurred or reduced central vision due to thinning of the macula. The macula is the part of the retina ...

The pharmaceutical industry is increasingly focused on developing pathway-based therapies for dry AMD, with promising treatments like ALK-001 and LBS-008 in trials, though a combination approach ...

Dry macular degeneration is a common eye disorder among people aged above 50 years. It causes blurred or reduced central vision due to thinning of the macula. The macula is the part of the retina ...